Hint mode is switched on Switch off

Anixa Biosciences, ordinary share
ANIX, US03528H1095

Add a stock to WL
Anixa Biosciences, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in
API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds
  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Issuer

Profile
By using the body's immune system, Anixa Biosciences, Inc. (former ITUS Corporation) is taking multiple approaches to fighting cancer-developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those ...
By using the body's immune system, Anixa Biosciences, Inc. (former ITUS Corporation) is taking multiple approaches to fighting cancer-developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. Anixa is developing the Cchek platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Anixa is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.
  • Issuer
  • Full borrower / issuer name
    Anixa Biosciences, Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    ANIX
  • Placement
    24.03.2021
  • Lock up period
    180
  • Number of papers
    4,285,715
  • Volume of raised funds
    22.5 mln USD
  • Placement share
    13.64%
  • Final placement price
    5.25 USD
  • Price change since placement date
    -52%
  • By capitalization
    164.94 mln USD

Related Stock indices

Registration is required to get access.